510(k) K260026
K260026 is an FDA 510(k) premarket notification submitted by Roche Diagnostics for the device "Tina-quant Cardiac high sensitivity CRP III". The FDA issued a decision of Substantially Equivalent on April 2, 2026. The device falls under product code NQD (Cardiac C-Reactive Protein, Antigen, Antiserum, And Control), a Class II device regulated under 21 CFR 866.5270. Roche Diagnostics has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- April 2, 2026
- Date Received
- January 5, 2026
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Cardiac C-Reactive Protein, Antigen, Antiserum, And Control
- Device Class
- Class II
- Regulation Number
- 866.5270
- Review Panel
- IM
- Submission Type
In vitro diagnostic test to measure C-reactive protein for the purpose of making cardiac risk assessments.